12.8%, respectively) and the proportion of participants prescribed SGLT2 inhibitors (20.4% vs
Tirzepatide is a dual-action medication that activates both GLP-1 and GIP receptors
If youre combining semaglutide with testosterone, they might stick closer to confirming your testosterone every three months, he says
Metabolic syndrome, characterized by abdominal obesity, elevated triglycerides, low HDL-C, hypertension, and insulin resistance, confers increased cardiovascular risk
Spironolactone users already have altered potassium metabolism, making them more sensitive to factors that shift kidney performance
Wegovy also has an FDA approval for cardiovascular risk reduction (March 2024), which makes it attractive for coverage